洲明科技 reported revenue of ¥3.55B for the period ended 2026-06-30, -2.9% year on year. Net income was ¥0.03B, a 0.9% net margin on a 25.2% gross margin. The largest revenue line is 智慧显示 at 93% of the total. Free cash flow for the period was ¥0.34B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥3.55B | -2.9% |
| Gross profit | ¥0.89B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.03B | -73.1% |
| Gross margin | 25.2% | Net margin 0.9% |
| Revenue Q/Q | +53.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 智慧显示 | ¥3.31B | 93.1% |
| 智能照明 | ¥0.22B | 6.2% |
| 其他 | ¥0.03B | 0.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥2.66B | 74.8% |
| R&D | ¥0.17B | 4.9% |
| SG&A | ¥0.65B | 18.2% |
| Tax & other | ¥-0.00B | -0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥10.12B |
| Total liabilities | ¥5.54B |
| Shareholders' equity | ¥4.58B |
| Equity / assets | 45.2% |
| Operating cash flow | ¥0.39B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥0.34B |
| Cash conversion (OCF / net income) | 477% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
金城医药 ・ 开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies